In summary, ZDV activates the p53 signaling pathway by targeting and inhibiting ABCC5, while potentially exerting stronger anti-HCC effects through other synergistic mechanisms, providing a novel multi-target intervention strategy for HCC treatment. The gene discussed is TP53; the disease is hepatocellular carcinoma.